Inhibitory effect of vemurafenib combined with panobinostat on human anaplastic thyroid cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited treatment options.
• Novel therapeutic strategies are urgently needed for ATC.
• This study explores the combined effect of Vemurafenib and Panobinostat on ATC cells.

Purpose of the Study:

• To investigate the combined inhibitory effect of Vemurafenib (Ve) and Panobinostat (Pa) on human ATC cell lines (FRO and ARO).
• To elucidate the underlying molecular mechanisms of this combined therapy.

Main Methods:

• Cell proliferation, synergy, migration, invasion, apoptosis, and glucose consumption were assessed using various assays (CCK-8, CompuSyn, Transwell, wound healing, apoptosis assays).
• Gene and protein expression of key molecular markers, including sodium iodide symporter (NIS) and glucose transporter 1 (GLUT1), were analyzed by RT-qPCR, Western blotting, and immunofluorescence.

Main Results:

• Vemurafenib and Panobinostat demonstrated a synergistic effect in inhibiting ATC cell proliferation.
• The combination significantly suppressed cell migration, invasion, and glucose consumption while enhancing apoptosis.
• Upregulation of NIS and related molecules, alongside downregulation of GLUT1, was observed with the combined treatment.

Conclusions:

• The combination of Vemurafenib and Panobinostat exerts a synergistic inhibitory effect on ATC cell growth and metastasis.
• This drug combination promotes apoptosis and cellular redifferentiation in ATC cells.
• Vemurafenib and Panobinostat represent a promising therapeutic strategy for anaplastic thyroid cancer.